75. A critical situational decision needs to be made about whether to release a new drug to market based on clinical trial results. If the trial had low statistical power, what is the urgency for a biostatistician’s caution?
A.
To immediately recommend approval.
B.
To caution that a non-significant result might be due to low power (Type II error) rather than true ineffectiveness, necessitating further investigation.
✓
C.
To ignore the power and focus on the p-value.
D.
To recommend disapproval regardless of findings.
📖 Additional Information
To immediately recommend approval.
To caution that a non-significant result might be due to low power (Type II error) rather than true ineffectiveness, necessitating further investigation.
